Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last --
Change Today 0.00 / 0.00%
Volume 0.0
4523 On Other Exchanges
4523 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

eisai co ltd (4523) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for EISAI CO LTD (4523)

Related News

No related news articles were found.

eisai co ltd (4523) Related Businessweek News

No Related Businessweek News Found

eisai co ltd (4523) Details

Eisai Co., Ltd. manufactures and sells pharmaceutical products worldwide. The company offers oncology-related products, such as Halaven, an anticancer agent; Aloxi, an antiemetic agent; and Fragmin, an injectable anticlotting agent, as well as Symbenda/Treakisym, a treatment for low-grade non-Hodgkin's lymphoma and other types of lymphatic cancer. It also provides Aricept, an anti-Alzheimer's agent; Pariet/AcipHex, a proton-pump inhibitor; and Humira, a human anti-TNF-a monoclonal antibody. In addition, the company offers epilepsy products comprising Zonegran, Zebinix, and Fycompa, which are antiepileptic agents; and Inovelon/BANZEL for the treatment of Lennox-Gastaut syndrome, as well as consumer healthcare (over-the-counter) products, which include vitamin B2 preparation Chocola BB Plus. Further, it provides Methycobal, a peripheral neuropathy treatment; Warfarin, an oral anticoagulant; Actonel, an osteoporosis treatment; Selbex for the treatment of gastritis/gastric ulcer; BELVIQ, an antiobesity agent; Stronger Neo-Minophagen C/Glycyron tablets for liver disease/allergic disease treatment; Lyrica, a treatment for postherpetic neuralgia; and Lunesta, a treatment for insomnia. Additionally, the company is involved in the research and development of various products under the areas of oncology, vascular and immunological reaction, gastrointestinal and hepatic disorders, and neurology. It has strategic partnerships with Quintiles Inc.; SFJ Pharma Ltd.; Biogen Idec, Inc.; BioArctic Neuroscience AB; FORMA Therapeutics, Inc.; Epizyme, Inc.; PRISM BioLab Co., Ltd.; Verastem, Inc.; and Halozyme Therapeutics, Inc. for the discovery and development of various products. Eisai Co., Ltd. has research collaborations with the Liverpool School of Tropical Medicine and the University of Liverpool. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.

10,183 Employees
Last Reported Date: 06/19/15
Founded in 1941

eisai co ltd (4523) Top Compensated Officers

Chief Executive Officer, Representative Corpo...
Total Annual Compensation: ¥119.0M
Senior Vice President, Chief Executive Office...
Total Annual Compensation: ¥110.0M
Vice President and President of Eisai Global ...
Total Annual Compensation: ¥68.0M
Vice President, President of Eisai Inc and Ch...
Total Annual Compensation: ¥63.0M
Vice President, President of Neuroscience & G...
Total Annual Compensation: ¥97.0M
Compensation as of Fiscal Year 2015.

eisai co ltd (4523) Key Developments

Eisai to Commence Two Joint Research Programs Toward Development of New Antimalarial Medicines

Eisai Co., Ltd. entered into two joint research agreements for the development of new antimalarial medicines. The first of these agreements is a joint development program with the Liverpool School of Tropical Medicine and the University of Liverpool. Under this agreement, the three parties will conduct preclinical development of a new antimalarial candidate compound E209. Research so far has shown that E209 is rapidly acting and shows efficacy against all types of malaria parasites, which means that it could be effective in patients for whom artemisinin-based malaria treatments are ineffective due to resistance. The second agreement is a joint development program with the non-profit public-private product development partnership Medicines for Malaria Venture (Location: Geneva, Switzerland, "MMV"). Under this agreement, Eisai and MMV aim to ultimately identify antimalarial candidate compounds with novel mechanisms of action that will be effective against malaria parasites resistant to existing treatments, as well as prevent relapse and block transmission to mosquitoes. This involves the optimization of compounds developed by Eisai that inhibit the biosynthesis of glycosylphosphatidylinositol (GPI) necessary for the growth of malaria parasites, and of a hit series of compounds identified from Eisai's compound library through joint research with MMV.

Eisai Co., Ltd. Reports Consolidated Earnings Results for Six Months Ended September 30, 2015; Provides Earnings Outlook for the Year Ending March 31, 2016; Announces Dividend for Second Quarter of 2016, Payable on November 18, 2015; Provides Year End Dividend Outlook for the Year 2016

Eisai Co., Ltd. reported consolidated earnings results for six months ended September 30, 2015. For the period, the company’s revenue was ¥275,503 million against ¥269,056 million a year ago. Operating profit was ¥18,076 million against ¥18,020 million a year ago. Profit before income tax was ¥17,334 million against ¥16,327 million a year ago. Profit for the period attributable to owners of the parent was ¥11,030 million against ¥10,413 million a year ago. Diluted earnings per share attributable to owners of the parent were ¥38.50 against ¥36.46 a year ago. Net cash from operating activities was ¥43,789 million against ¥37,158 million a year ago. Purchases of property, plant and equipment was ¥2,855 million against ¥7,675 million a year ago. Purchases of intangible assets were ¥30,811 million against ¥2,562 million a year ago. Ratio of equity attributable to owners of the parent was 59.4% against 56.8% a year ago. For the second quarter of 2016, the company announced dividend of ¥70.00 per share, payable on November 18, 2015. The company expects year end dividend of ¥80.00 per share for the year ending March 31, 2016. For the year ending March 31, 2016, the company expects revenue of ¥556,500 million, operating profit of ¥46,000 million, profit before income tax of ¥42,800 million and profit of ¥27,000 million or ¥93.83 per basic share.

Eisai Co., Ltd., Board Meeting, Jul 31, 2015

Eisai Co., Ltd., Board Meeting, Jul 31, 2015. Agenda: To consider the continuation of the Policy for Protection of the Company's Corporate Value and Common Interests of Shareholders.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4523:JP ¥8,225.00 JPY +31.00

4523 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Almirall SA €17.17 EUR +0.16
Ironwood Pharmaceuticals Inc $12.26 USD +0.01
Nektar Therapeutics $15.64 USD +0.58
Shire PLC 4,639 GBp +42.00
Valeant Pharmaceuticals International Inc C$117.89 CAD +2.54
View Industry Companies

Industry Analysis


Industry Average

Valuation 4523 Industry Range
Price/Earnings 52.1x
Price/Sales 4.1x
Price/Book 3.9x
Price/Cash Flow 52.1x
TEV/Sales 3.4x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact EISAI CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at